...how low the pps is on Genta with such positive results pouring in from the Agenda trial. It really is amazing. Genasense has a SERIOUS opportunity for approval with the Agenda trial results. It's a randomized, double-blind, placebo driven, world wide clinical trial that's producing results that are undeniable with respect to effectiveness and safety.
The FDA is going to be under serious pressure, and I promise you the oncology community is going to make sure that there are oncologists on the panel this time around.
Trading at .008? Are you kidding me? Genta is worth significantly more than that without a groundbreaking drug like Genasense. Look at their pipeline, it speaks for itself.
If Genasense gets approved, it will be the news of the year in the oncology sector. Pretty exciting stuff, and if approval is based on trial results, Genasense gets approved unanimously.
Here are the interim results from the randomized, double-blind, placebo driven, world wide clinical trial of Genasense. How can you deny these results along with the proven safety? You can't.
News 
Market Data 
Discover 
AI
